Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon

Table 3 Killer immunoglobulin receptor gene frequencies among study participants vaccinated against hepatitis B virus (protected and non-protected by hepatitis B vaccine) n (%)

KIR genes	Anti-HBsAg < 10 mIU/mL (n = 22)	Anti-HBsAg ≥ 10 mIU/mL (n = 52)	Test1	OR (95%CI)	P value
2DL2	14 (63.60)	27 (51.90)	0.858	0.62 (0.22-1.72)	0.446
2DL3	18 (81.80)	45 (86.40)	FET	1.43 (0.37-5.48)	0.723
2DL5A	8 (36.40)	13 (25.00)	0.982	0.58 (0.20-1.70)	0.4
2DL5B	5 (22.70)	19 (36.50)	1.346	1.97 (0.62-6.16)	0.289
2DS1	11 (50.00)	19 (36.50)	1.162	0.58 (0.21-1.58)	0.31
2DS2	14 (63.60)	26 (50.00)	1.157	0.57 (0.21-1.59)	0.318
2DS3	9 (40.90)	23 (44.20)	0.069	1.15 (0.42-3.15)	0.804
2DS4*001/002	8 (36.40)	20 (38.40)	0.029	1.09 (0.39-3.072)	1.00
2DS4*003/007	19 (86.40)	41 (78.85)	FET	0.59 (0.15-2.36)	0.534
2DS5	10 (45.50)	17 (32.60)	1.087	0.58 (0.21-1.62)	0.428
3DS1	11 (50.00)	21 (40.40)	0.582	0.68 (0.25-1.85)	0.608
3DP*001/002/004	6 (27.30)	9 (17.30)	FET	0.56 (0.17-1.82)	0.355

¹The statistical test performed to compare the frequencies of KIR gene expression among vaccinated and non-vaccinated study participants where by FET refers to Fisher’s exact test and the rest of the values represent the Pearson χ² value. We compared the frequencies of KIR genes with enough variability between study participants that were vaccinated against hepatitis B virus. The vaccinated participants were divided for this analysis into 2 groups depending on the level of anti-HBsAg. Anti-HBsAg < 10 mIU/mL, not protected against hepatitis B virus infection; anti-HBsAg ≥ 10 mIU/mL, protected against hepatitis B virus infection as a result of vaccination. KIR: Killer immunoglobulin receptor; FET: Fisher-exact test; HBsAg: Hepatitis B surface antigen. OR: Odds ratio.